Total Payments
$407,824
2024 Payments
$3,446
Companies
25
Transactions
172
Payment Breakdown by Category
Research$239,395 (58.7%)
Consulting$158,761 (38.9%)
Travel$6,085 (1.5%)
Food & Beverage$3,583 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $239,395 | 28 | 58.7% |
| Consulting Fee | $158,761 | 52 | 38.9% |
| Travel and Lodging | $6,085 | 22 | 1.5% |
| Food and Beverage | $3,583 | 70 | 0.9% |
Payments by Type
Research
$239,395
28 transactions
General
$168,429
144 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $193,801 | 4 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $91,580 | 21 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $52,681 | 28 | $0 (2022) |
| Allergan, Inc. | $21,951 | 15 | $0 (2020) |
| PFIZER INC. | $19,533 | 8 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $14,330 | 13 | $0 (2020) |
| Eli Lilly and Company | $4,377 | 5 | $0 (2023) |
| Sage Therapeutics, Inc. | $1,960 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,526 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,395 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,446 | 16 | E.R. Squibb & Sons, L.L.C. ($1,526) |
| 2023 | $36,493 | 24 | PFIZER INC. ($19,533) |
| 2022 | $138,033 | 36 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($84,254) |
| 2021 | $184,824 | 23 | Biohaven Pharmaceuticals, Inc. ($91,580) |
| 2020 | $131.06 | 5 | Vanda Pharmaceuticals Inc. ($54.68) |
| 2019 | $5,069 | 13 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($4,800) |
| 2018 | $17,017 | 33 | Sunovion Pharmaceuticals Inc. ($14,246) |
| 2017 | $22,812 | 22 | Allergan Inc. ($21,072) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $202.27 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.93 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.94 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $412.19 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $202.27 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $78.28 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2024 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $536.00 | General |
| 04/15/2024 | Sage Therapeutics, Inc. | ZURZUVAE (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: PSYCHIATRY/PSYCHOLOGY | ||||||
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $889.51 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $328.37 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $308.03 | General |
| 12/27/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,335.30 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 12/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $20.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/26/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $130.39 | General |
| 10/26/2023 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $100.60 | General |
| Category: Neurology | ||||||
| 10/11/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,410.20 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 09/20/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,335.30 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 08/24/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $826.83 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/03/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,937.50 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 06/10/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $316.38 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $189,001 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $19,333 | 2 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $18,686 | 6 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,800 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $3,839 | 2 |
| AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | Allergan Inc. | $1,670 | 1 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $846.83 | 2 |
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Biogen, Inc. | $696.81 | 8 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $260.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $168.75 | 1 |
| NN6535-4725, NN6535-4730 | Novo Nordisk AS | $94.08 | 1 |
About Dr. Thomas Shiovitz, MD
Dr. Thomas Shiovitz, MD is a Psychiatry healthcare provider based in Sherman Oaks, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942309851.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Shiovitz, MD has received a total of $407,824 in payments from pharmaceutical and medical device companies, with $3,446 received in 2024. These payments were reported across 172 transactions from 25 companies. The most common payment nature is "" ($239,395).
Ad
Practice Information
- Specialty Psychiatry
- Location Sherman Oaks, CA
- Active Since 09/21/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1942309851
Products in Payments
- NURTEC ODT (Drug) $19,882
- REXULTI (Drug) $4,823
- Non-Covered Product (Drug) $1,106
- CNP520 (Drug) $930.31
- ZAVZPRET (Drug) $846.83
- ADUHELM (Biological) $234.55
- LATUDA (Drug) $169.83
- VRAYLAR (Drug) $122.80
- Rybelsus (Drug) $94.08
- Fanapt (Drug) $64.64
- BRINTELLIX (Drug) $58.78
- HETLIOZ (Drug) $54.68
- SPRAVATO (Drug) $50.80
- NUPLAZID (Drug) $41.16
- BELSOMRA (Drug) $30.49
- UBRELVY (Drug) $28.49
- API015 (Drug) $25.45
- INGREZZA (Drug) $24.86
- Trintellix (Drug) $24.82
- ZURZUVAE (Drug) $18.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Sherman Oaks
Martin Schuster, M.d, M.D
Psychiatry — Payments: $1.6M
Psychiatry $1.6M
Nitin Nanda, M.d, M.D
Psychiatry — Payments: $90,412
Psychiatry $90,412
Dr. Xue Zhong, Md, MD
Psychiatry — Payments: $44,134
Psychiatry $44,134
Alexander Korchmarev, M.d, M.D
Psychiatry — Payments: $5,419
Psychiatry $5,419
Sepehr Broukhim, D.o, D.O
Psychiatry — Payments: $5,042
Psychiatry $5,042
Dr. Neda Javaherian, M.d, M.D
Psychiatry — Payments: $4,315
Psychiatry $4,315